[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558155":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":26,"responsibleParty":38,"collaborators":26,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":26,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":26,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":26,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Western Galilee Hospital-Nahariya","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"oxytocin plus papaverine","ACTIVE_COMPARATOR","Intervention Group: Combined use of papaverine (80 mg intravenous mg in 100 mL saline once concurrent with the start of oxytocin) and oxytocin.",[13],"Drug: Papaverine",{"label":15,"type":16,"description":17,"interventionNames":18},"oxytocin alone","PLACEBO_COMPARATOR","Control Group: Oxytocin plus 100 mL saline.",[19],"Drug: normal saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Papaverine","papaverine a smooth muscle relaxant",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"normal saline","normal saline 0.9% 100 cc",[15],[29],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"inshirah sgayer","CONTACT","0508890662","inshirah.sg.sh@gmail.com",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Inshirah Sgayer","DR inshirah sgayer galilee medical center","100558155","papaverine-and-oxytocin-vs-oxytocin-alone-in-labor-induction-100558155",false,"NCT06547437","Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction","\"Evaluating the Effectiveness of Papaverine as an Adjunct to Oxytocin for Labor Induction: A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Women with a singleton pregnancy Over the age of 18 Term (between 37-42 weeks of gestation) A medical decision for labor induction using oxytocin. Cephalic presentation Viable fetus nulliparity\n\nExclusion Criteria:\n\n* parity \\>1\n* Twin pregnancy Women with a previous cesarean section Severe fetal anomalies Women with psychiatric disorders, including depression and schizophrenia. Contraindication to vaginal delivery Women unable to sign the consent form Women known to have SVT (supraventricular tachycardia). Women with a heart rate over 100 or arrhythmia Known sensitivity to any component of the drug Liver disease",true,"FEMALE","18 Years","50 Years",{"count":54,"type":55},126,"ESTIMATED","INTERVENTIONAL",[58],"NA","This study aims to evaluate the efficacy and safety of combining papaverine with oxytocin for labor induction compared to oxytocin alone",[61,62],"Induced; Birth","Labor Onset and Length Abnormalities","NOT_YET_RECRUITING","2024-09-10",{"date":66,"type":67},"2024-09-19","ACTUAL",{"date":69,"type":55},"2024-09",{"date":71,"type":55},"2025-12",{"name":5,"class":6}]